Home - Translational Lung Cancer Research

New Impact Factor for Translational Lung Cancer Research: 6.498

We are pleased to announce that the Translational Lung Cancer Research (TLCR) has attained its latest impact factor update for the 2020 citation year: 6.498.

Immunotherapy in Other Thoracic Malignancies and Uncommon Populations

In this special series of Translational Lung Cancer Research about “Immunotherapy in other thoracic malignancies and uncommon populations”, a group of renowned international specialists involved in the management of thoracic malignancies present a comprehensive and timely review of state-of-the-art of ICI in thoracic malignancies, discussing the lights and shadows of ICIs, either in under-represented patients with NSCLC in clinical trials, as well as the efficacy of ICIs in thoracic malignancies other than NSCLC.

Lung Cancer and The Immune System

This series of Transl Lung Cancer Res will evaluate current clinical evidence in the still-evolving understanding of the role of ICI in oncogene addicted NSCLC, and the potential pulmonary toxicity associated with ICI.

Lung cancer screening

This special series gives an overview of current evidence and addresses a number of relevant questions related to the implementation of lung cancer screening. We specifically have a close look at the target population, the role of the radiologist in lung cancer screening, diagnosis and management of screen-detected nodules in Asia and Europe, the current role of sublobar resection, implantation of screening programs and finally, the psychological impact of lung cancer screening.

Radiotherapy in thoracic malignancies

In this series of Translational Lung Cancer Research, a group of renowned world experts presents the comprehensive and timely review of state-of-the-art radiation therapy in lung cancer and other thoracic malignancies.

Reviewer of the Month (2020-21)

Over the years, many TLCR reviewers have made outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Implementation of CT-based screening of lung cancer

In this special series, a group of the most outstanding experts and researchers of all aspects of lung cancer screening answers the most important questions about the introduction of a screening program as well as the development of this new field of medicine.

TLCR Annual Report 2020

Welcome to the 2020 annual report for Translational Lung Cancer Research. In 2020, the TLCR has continued its mission to increase the quality and impact of the journal, and to provide readers with a novel, well-organized, informative, enlightening and educational journal.

We would like to sincerely thank our Editorial Board Members, Guest editors, Reviewers, Authors, Readers for all your supports and contributions to TLCR in 2020, and we look forward to continuing our work with you in the new year.

Translational Lung Cancer Research to publish monthly beginning in January 2021

Since its initiation in 2012, Translational Lung Cancer Research (TLCR) has been developing at a speedy pace with increasing readership and citations. In order to better serve the growing needs of readers and authors, the TLCR will move from a bimonthly to a monthly publication schedule beginning in January 2021.

‹ ›

Vol 10, No 7 (July, 2021)

About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: editor@tlcr.org
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

Original Article

Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study

Alexander Mathilakathu, Sabrina Borchert, Michael Wessolly, Elena Mairinger, Hendrik Beckert, Julia Steinborn, Thomas Hager, Daniel C. Christoph, Jens Kollmeier, Jeremias Wohlschlaeger, Thomas Mairinger, Kurt Werner Schmid, Robert F. H. Walter, Luka Brcic, Fabian D. Mairinger

PDF Pages: 3030-3042 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Diagnosis-to-surgery interval and survival for different histologies of stage I–IIA lung cancer

Lu Zhang, Mei-Chin Hsieh, Lior Rennert, Paige Neroda, Xiao-Cheng Wu, Chindo Hicks, Jiande Wu, Ronald Gimbel

PDF Pages: 3043-3058 Full Text Reporting Checklist Peer Review File COI Form Open Access

Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open- label phase 2 study (CLEAR)

Hibiki Udagawa, Eri Sugiyama, Toshiyuki Harada, Shinji Atagi, Ryo Koyama, Satoshi Watanabe, Yukiko Nakamura, Daijiro Harada, Osamu Hataji, Fumihiro Tanaka, Hiroshi Kida, Miyako Satouchi, Ken Maeno, Akira Inoue, Kiyotaka Yoh, Yuki Yamane, Yoshiko Urata, Hiroshige Yoshioka, Takeharu Yamanaka, Koichi Goto

PDF Pages: 3059-3070 Full Text Reporting Checklist Trial Protocol Data Sharing Statement COI Form Open Access

Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab

Khalid Jazieh, Mohamed Gad, Anas Saad, Wei Wei, Nathan A. Pennell

PDF Pages: 3071-3078 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies

Mary Zhang, Julie A. Hong, Tricia F. Kunst, Colleen D. Bond, Cara M. Kenney, Cheryl L. Warga, Javier Yeray, Min-Jung Lee, Akira Yuno, Sunmin Lee, Markku Miettinen, R. Taylor Ripley, Chuong D. Hoang, Sacha Gnjatic, Jane B. Trepel, David S. Schrump

PDF Pages: 3079-3092 Full Text Reporting Checklist Trial Protocol Data Sharing Statement COI Form Open Access

Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV

Wolfgang M. Brueckl, Martin Reck, Achim Rittmeyer, Jens Kollmeier, Claas Wesseler, Gunther H. Wiest, Petros Christopoulos, Albrecht Stenzinger, Amanda Tufman, Petra Hoffknecht, Bernhard Ulm, Fabian Reich, Joachim H. Ficker, Eckart Laack

PDF Pages: 3093-3105 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups

Francesco Passiglia, Antonio Galvano, Valerio Gristina, Nadia Barraco, Marta Castiglia, Alessandro Perez, Maria La Mantia, Antonio Russo, Viviana Bazan

PDF Pages: 3106-3119 Full Text Reporting Checklist Peer Review File COI Form Open Access

Shared decision-making for prophylactic cranial irradiation in extensive-stage small-cell lung cancer: an exploratory study

Anshu Ankolekar, Dirk De Ruysscher, Bart Reymen, Ruud Houben, Andre Dekker, Cheryl Roumen, Rianne Fijten

PDF Pages: 3120-3131 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease

Yusuke Sato, Satoshi Watanabe, Takeshi Ota, Kohei Kushiro, Toshiya Fujisaki, Miho Takahashi, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Satoshi Hokari, Rie Kondo, Masachika Hayashi, Hiroyuki Ishikawa, Takao Miyabayashi, Tetsuya Abe, Satoru Miura, Hiroshi Tanaka, Masaaki Okajima, Masaki Terada, Takashi Ishida, Akira Iwashima, Kazuhiro Sato, Hirohisa Yoshizawa, Nobumasa Aoki, Yasuyoshi Ohshima, Toshiyuki Koya, Toshiaki Kikuchi

PDF Pages: 3132-3143 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer

Fangqiu Fu, Chaoqiang Deng, Zhexu Wen, Zhendong Gao, Yue Zhao, Han Han, Shanbo Zheng, Shengping Wang, Yuan Li, Hong Hu, Yang Zhang, Haiquan Chen

PDF Pages: 3144-3154 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1

Shuangshuang Mao, Sufei Zheng, Zhiliang Lu, Xinfeng Wang, Yan Wang, Guochao Zhang, Haiyan Xu, Jianbing Huang, Yuanyuan Lei, Chengming Liu, Nan Sun, Jie He

PDF Pages: 3155-3172 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Risk-score model to predict prognosis of malignant airway obstruction after interventional bronchoscopy

Minlin Jiang, Hao Xu, Dongmei Yu, Li Yang, Wenhui Wu, Hao Wang, Hui Sun, Jun Zhu, Wencheng Zhao, Qiyu Fang, Jia Yu, Peixin Chen, Shengyu Wu, Zixuan Zheng, Liping Zhang, Likun Hou, Huixian Zhang, Ye Gu, Yayi He

PDF Pages: 3173-3190 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy

Xuanye Zhang, Dan Tian, Yue Chen, Chen Chen, Li-Na He, Yixin Zhou, Haifeng Li, Zuan Lin, Tao Chen, Yuhong Wang, Alessandro Russo, Ernest Nadal, Francesco Passiglia, Ross Andrew Soo, Satoshi Watanabe, Teresa Moran, In-Jae Oh, Sha Fu, Shaodong Hong, Li Zhang

PDF Pages: 3191-3202 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

A simplified model for determining the cutting plane during thoracoscopic anatomical partial lobectomy of the right lower lobe

Yun Liu, Bin Qiu, Songlin Zhang, Chaobing Liu, Ming Yan, Lailong Sun, Dominique Gossot, Takahiro Homma, Fariha Sheikh, Peter J. Kneuertz

PDF Pages: 3203-3212 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutations

Kai Guo, Changjian Shao, Lu Han, Honggang Liu, Zhiqiang Ma, Yang Yang, Yingtong Feng, Minghong Pan, Mariacarmela Santarpia, Maria Carmo-Fonseca, Catarina Silveira, Kye Young Lee, Jing Han, Xiaofei Li, Xiaolong Yan

PDF Pages: 3213-3225 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Breast metastases from primary lung cancer: a retrospective case series on clinical, ultrasonographic, and immunohistochemical features

Bo Wang, Ying Jiang, Shi Yu Li, Rui Lan Niu, Justin D. Blasberg, Jussuf T. Kaifi, Gang Liu, Zhi Li Wang

PDF Pages: 3226-3235 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma

Xiao-Dong Jiao, Li-Ren Ding, Chuan-Tao Zhang, Bao-Dong Qin, Ke Liu, Lian-Ping Jiang, Xi Wang, Li-Ting Lv, Hao Ding, Dao-Ming Li, Hui Yang, Xue-Qin Chen, Wen-Yu Zhu, Ying Wu, Yan Ling, Xi He, Jun Liu, Lin Shao, Hao-Zhe Wang, Yan Chen, Jing-Jing Zheng, Naoki Inui, Yuan-Sheng Zang

PDF Pages: 3236-3250 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

The prognostic role of the Transducin-like Enhancer of split protein family in lung adenocarcinoma

Qianli Ma, Fei Xiao, Yang Hao, Zhiyi Song, Jin Zhang, Chaozeng Si, Chaoyang Liang, Deruo Liu

PDF Pages: 3251-3263 Full Text Reporting Checklist COI Form Open Access

Review Article

A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future

Sijia Ren, Anyi Xu, Yilian Lin, D. Ross Camidge, Massimo Di Maio, Raffaele Califano, Toyoaki Hida, Antonio Rossi, Nicolas Guibert, Chengchu Zhu, Jianfei Shen

PDF Pages: 3264-3275 Full Text Reporting Checklist COI Form Open Access

Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review

Miaozhen Lin, Ben G. L. Vanneste, Qiwen Yu, Zebin Chen, Jiayu Peng, Xiuyu Cai

PDF Pages: 3276-3291 Full Text Reporting Checklist COI Form Open Access

Case Report

Adrenal crisis and acute exacerbation of interstitial lung disease after thymoma needle biopsy: a case report and literature review

Hengyi Yan, Qi Qi, Kai Zhang, Bing He, Guoming Chu, Guan Wang, Hua Wen, Yanyan Zhao, Hongxu Liu, Li Zhao, Yu Chen

PDF Pages: 3292-3302 Full Text Reporting Checklist Peer Review File COI Form Open Access

Acute anti-Ma2 paraneoplastic encephalitis associated to pembrolizumab: a case report and review of literature

Víctor Albarrán, Javier Pozas, Fernando Rodríguez, Ángela Carrasco, Elena Corral, Yolanda Lage, Pablo Álvarez-Ballesteros, Ainara Soria, Pilar Garrido

PDF Pages: 3303-3311 Full Text Reporting Checklist Peer Review File COI Form Open Access

Mobile 3-dimensional (3D) C-arm system-assisted transbronchial biopsy and ablation for ground-glass opacity pulmonary nodules: a case report

Junxiang Chen, Fangfang Xie, Xiaoxuan Zheng, Ying Li, Shuaiyang Liu, Kevin C. Ma, Taichiro Goto, Tobias Müller, Edward D. Chan, Jiayuan Sun

PDF Pages: 3312-3319 Full Text Reporting Checklist COI Form Open Access

Editorial on Oligometastatic NSCLC: Definition and Treatment Opportunities¹

Oligometastatic non-small cell lung cancer: from biology to clinical practice

Maurizio V. Infante, Thierry Berghmans

PDF Pages: 3320-3323 Full Text COI Form Open Access

Local for advanced, is this a paradox?

Maristella Bungaro, Chiara Paratore, Paolo Bironzo, Silvia Novello

PDF Pages: 3324-3328 Full Text COI Form Open Access

Review Article on Oligometastatic NSCLC: Definition and Treatment Opportunities¹

Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review

Jill F. Mentink, Marthe S. Paats, Daphne W. Dumoulin, Robin Cornelissen, Joris B. W. Elbers, Alexander P. W. M. Maat, Jan H. von der Thüsen, Anne-Marie C. Dingemans

PDF Pages: 3329-3338 Full Text Reporting Checklist COI Form Open Access

Epidemiology of oligometastatic non-small cell lung cancer: results from a systematic review and pooled analysis

Elisa Gobbini, Luca Bertolaccini, Niccolò Giaj-Levra, Jessica Menis, Matteo Giaj-Levra

PDF Pages: 3339-3350 Full Text Reporting Checklist Peer Review File COI Form Open Access

Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer

Sawsan Rashdan, Puneeth Iyengar, John D. Minna, David E. Gerber

PDF Pages: 3351-3368 Full Text Reporting Checklist Peer Review File COI Form Open Access

A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done

Lorenzo Belluomini, Alessandra Dodi, Alberto Caldart, Dzenete Kadrija, Marco Sposito, Miriam Casali, Giulia Sartori, Miriam Grazia Ferrara, Alice Avancini, Emilio Bria, Jessica Menis, Michele Milella, Sara Pilotto

PDF Pages: 3369-3384 Full Text Reporting Checklist COI Form Open Access

Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review

Diego Cortinovis, Umberto Malapelle, Fabio Pagni, Alessandro Russo, Giuseppe Luigi Banna, Elisa Sala, Christian Rolfo

PDF Pages: 3385-3400 Full Text Reporting Checklist COI Form Open Access

Clinical prognostic factors in surgically treated oligometastatic non-small cell lung cancer: a systematic review

Luca Bertolaccini, Monica Casiraghi, Giulia Sedda, Filippo de Marinis, Lorenzo Spaggiari

PDF Pages: 3401-3408 Full Text Reporting Checklist COI Form Open Access

The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review

Lawek Berzenji, Sophie Debaenst, Jeroen M. H. Hendriks, Suresh Krishan Yogeswaran, Patrick Lauwers, Paul E. Van Schil

PDF Pages: 3409-3419 Full Text Reporting Checklist COI Form Open Access

Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review

Nora Sundahl, Yolande Lievens

PDF Pages: 3420-3431 Full Text Reporting Checklist COI Form Open Access

Alternative methods for local ablation—interventional pulmonology: a narrative review

Gerard Olive, Rex Yung, Henry Marshall, Kwun M. Fong

PDF Pages: 3432-3445 Full Text Reporting Checklist COI Form Open Access

Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review

Michael C. Tjong, Alexander V. Louie, Puneeth Iyengar, Benjamin J. Solomon, David A. Palma, Shankar Siva

PDF Pages: 3446-3456 Full Text Reporting Checklist COI Form Open Access

Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies—a narrative review

Vincent Fallet, Lise Matton, Antoine Schernberg, Anthony Canellas, François H. Cornelis, Jacques Cadranel

PDF Pages: 3457-3472 Full Text Reporting Checklist COI Form Open Access

Current and future research efforts in oligometastatic non-small cell lung cancer—a systematic review

Mariana Brandão, Valérie Durieux, Thierry Berghmans

PDF Pages: 3473-3485 Full Text Reporting Checklist COI Form Open Access

How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review

Jordi Remon, Jessica Menis, Antonin Levy, Dirk K. M. De Ruysscher, Lizza E. L. Hendriks

PDF Pages: 3486-3502 Full Text Reporting Checklist COI Form Open Access

Disclosure:

1. The series “Oligometastatic NSCLC: definition and treatment opportunities” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Maurizio V. Infante and Thierry Berghmans served as the unpaid Guest Editors for the series.

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Editorial

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M

Daniel B. Costa, Susumu S. Kobayashi

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?

Yoshihisa Kobayashi, Tetsuya Mitsudomi

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Javier de Castro Carpeño, Cristóbal Belda-Iniesta

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Non-small cell lung cancer: current treatment and future advances

Cecilia Zappa, Shaker A. Mousa

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

Po Yee Yip

Lung cancer molecular epidemiology in China: recent trends

Caicun Zhou

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention

Joanna Domagala-Kulawik

Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements

Cristina Teixidó, Niki Karachaliou, Vicente Peg, Ana Gimenez-Capitan, Rafael Rosell

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it

Christian Rolfo, Francesco Passiglia, Marta Castiglia, Luis E. Raez, Paul Germonpre, Ignacio Gil-Bazo, Karen Zwaenepoel, Annemieke De Wilde, Giuseppe Bronte, Antonio Russo, Jan P. Van Meerbeeck, Paul Van Schil, Patrick Pauwels

Highlighted Reports in European Lung Cancer Conference

Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines

Paul De Leyn, Christophe Dooms, Jaroslaw Kuzdzal, Didier Lardinois, Bernward Passlick, Ramon Rami-Porta, Akif Turna, Paul Van Schil, Frederico Venuta, David Waller, Walter Weder, Marcin Zielinski

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo

Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies

Charles B. Simone II, Stuart H. Burri, John H. Heinzerling

Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)

Richard D. Hall, Tri M. Le, Daniel E. Haggstrom, Ryan D. Gentzler

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis

Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song

BRAF mutations in non-small cell lung cancer

Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer

Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper

Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice

Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song

Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer

Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen

The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants

Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden

The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices

Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement

Hyojin Kim, Jin-Haeng Chung

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer

Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Clinical trials for lung cancer in China

Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Prognostic markers in lung cancer: is it ready for prime time?

Chang-Qi Zhu, Ming-Sound Tsao

Potential biomarkers for lung cancer screening

Gabriella Sozzi, Mattia Boeri

Particle therapy in non-small cell lung cancer

Zhongxing Liao, Charles B. Simone II

Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions

Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai

Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer

Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors

Suchit H. Patel, Andreas Rimner, Roger B. Cohen

Intraoperative near-infrared imaging of mesothelioma

Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal

BAP1, a tumor suppressor gene driving malignant mesothelioma

Mitchell Cheung, Joseph R. Testa

Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation

Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang

Immunotherapy for malignant pleural mesothelioma: current status and future directions

Jordan Dozier, Hua Zheng, Prasad S. Adusumilli

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer

Linda O’Flaherty, Harriet Wikman, Klaus Pantel

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?

Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Sumitra Mohan, Francesca Chemi, Ged Brady

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Derrick W. Su, Jorge Nieva

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer

Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Editorial

An alternative way to initiate Notch1 signaling in non-small cell lung cancer

Yi-Lin Yang, David Jablons, Liang You

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Fernando C. Santini, Siddharth Kunte, Alexander Drilon

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis

Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

China Lung Cancer Research Highlight

Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology

Maria Felice Brizzi, Paola Defilippi

Editorials

Dulanermin in cancer therapy: Still much to do

Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data

Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner

Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung

Pedro Mendez, Jose Luis Ramirez

Role of HGF/MET axis in resistance of lung cancer to contemporary management

Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr

Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review

Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Ceritinib

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Daniel B. Costa

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack

Lorenza Landi, Federico Cappuzzo

Nivolumab

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer

Arun Rajan, James L. Gulley

Brief Report

The role of Imaging and Radiation Oncology Core for precision medicine era of clinical trial

Ying Xiao, Mark Rosen

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung

Yoon Jin Cha, Hyo Sup Shim

Immunohistochemistry for predictive biomarkers in non-small cell lung cancer

Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Original Article

Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study

Takamasa Koga, Kenichi Suda, Masaya Nishino, Toshio Fujino, Shuta Ohara, Akira Hamada, Junichi Soh, Vijaya Tirunagaru, Avanish Vellanki, Robert C. Doebele, Tetsuya Mitsudomi

Surgical mediastinal lymph node staging for non-small-cell lung carcinoma

Pieter W. J. Lozekoot, Jean H. T. Daemen, Robert R. van den Broek, Jos G. Maessen, Michiel H. M. Gronenschild, Yvonne L. J. Vissers, Karel W. E. Hulsewé, Erik R. de Loos

Journal Highlight more

Translational Lung Cancer Research is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central, focusing on cutting-edge development on the transition from preclinical to clinical research, including but not limited to multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.